Ginsberg MS - Search Results

1

Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma.

Motzer RJ, Amato R, Todd M, Hwu WJ, Cohen R, Baselga J, Muss H, Cooper M, Yu R, Ginsberg MS, Needle M. Motzer RJ, et al. Among authors: ginsberg ms. Invest New Drugs. 2003 Feb;21(1):99-101. doi: 10.1023/a:1022928612511. Invest New Drugs. 2003. PMID: 12795534 Clinical Trial.

2

Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors.

Vuky J, McCaffrey J, Ginsberg M, Mariani T, Bajorin DF, Bosl GJ, Motzer RJ. Vuky J, et al. Invest New Drugs. 2000 Aug;18(3):265-7. doi: 10.1023/a:1006434008357. Invest New Drugs. 2000. PMID: 10958596 Clinical Trial.

3

Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.

Motzer RJ, Rakhit A, Ginsberg M, Rittweger K, Vuky J, Yu R, Fettner S, Hooftman L. Motzer RJ, et al. J Clin Oncol. 2001 Mar 1;19(5):1312-9. doi: 10.1200/JCO.2001.19.5.1312. J Clin Oncol. 2001. PMID: 11230473 Clinical Trial.

4

Phase II trial of thalidomide for patients with advanced renal cell carcinoma.

Motzer RJ, Berg W, Ginsberg M, Russo P, Vuky J, Yu R, Bacik J, Mazumdar M. Motzer RJ, et al. J Clin Oncol. 2002 Jan 1;20(1):302-6. doi: 10.1200/JCO.2002.20.1.302. J Clin Oncol. 2002. PMID: 11773183 Clinical Trial.

5

Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma.

Motzer RJ, Rakhit A, Thompson J, Gurney H, Selby P, Figlin R, Negrier S, Ernst S, Siebels M, Ginsberg M, Rittweger K, Hooftman L. Motzer RJ, et al. Ann Oncol. 2002 Nov;13(11):1799-805. doi: 10.1093/annonc/mdf288. Ann Oncol. 2002. PMID: 12419754 Free article. Clinical Trial.

6

Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma.

Drucker B, Bacik J, Ginsberg M, Marion S, Russo P, Mazumdar M, Motzer R. Drucker B, et al. Invest New Drugs. 2003 Aug;21(3):341-5. doi: 10.1023/a:1025472712456. Invest New Drugs. 2003. PMID: 14578682 Clinical Trial.

7

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI. Motzer RJ, et al. Among authors: ginsberg ms. J Clin Oncol. 2006 Jan 1;24(1):16-24. doi: 10.1200/JCO.2005.02.2574. Epub 2005 Dec 5. J Clin Oncol. 2006. PMID: 16330672 Clinical Trial.

8

Sunitinib in patients with metastatic renal cell carcinoma.

Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD. Motzer RJ, et al. Among authors: ginsberg ms. JAMA. 2006 Jun 7;295(21):2516-24. doi: 10.1001/jama.295.21.2516. JAMA. 2006. PMID: 16757724 Clinical Trial.

9

Long-term response with sunitinib for metastatic renal cell carcinoma.

Ronnen EA, Kondagunta GV, Ginsberg MS, Russo P, Motzer RJ. Ronnen EA, et al. Among authors: ginsberg ms. Urology. 2006 Sep;68(3):672.e19-20. doi: 10.1016/j.urology.2006.03.042. Epub 2006 Sep 18. Urology. 2006. PMID: 16979716

10

Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors.

Feldman DR, Kondagunta GV, Ginsberg MS, Ishill N, Patil S, Cestaro J, Obbens E, Sheinfeld J, Bosl GJ, Motzer RJ. Feldman DR, et al. Among authors: ginsberg ms. Invest New Drugs. 2007 Oct;25(5):487-90. doi: 10.1007/s10637-007-9059-2. Epub 2007 May 23. Invest New Drugs. 2007. PMID: 17520176 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

182 results

Search Page

Filters